Compare RCG & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCG | HOTH |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 18.0M |
| IPO Year | N/A | 2019 |
| Metric | RCG | HOTH |
|---|---|---|
| Price | $2.57 | $1.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 5.9K | ★ 249.4K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.52 | $0.66 |
| 52 Week High | $1.90 | $3.80 |
| Indicator | RCG | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 44.77 |
| Support Level | $2.50 | $1.13 |
| Resistance Level | $2.60 | $1.27 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 48.00 | 66.58 |
RENN Fund Inc is active in the financial services domain. It is a a registered, non-diversified, closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, oil and gas, medical chemicals, botanical products, etc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).